Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.bioMerieux, a developer of in vitro diagnostics for medical and industrial applications, has signed a licensing and development agreement with the German biotechnology company, ProteoSys, for Annexin 3, which will be used to develop a urine-based, confirmatory diagnostic test for prostate cancer.
Subscribe to our email newsletter
Annexin 3, also known as Anxa 3, would be used to provide better identification of patients with a high probability of prostate cancer, thereby reducing the number of unnecessary biopsies, said bioMerieux. The Anxa 3 test will be complementary to the tPSA and FPSA tests available on Vidas.
The first phase of research is beginning at bioMerieux, which will be followed by the development of a diagnostic test for the Vidas platform. While the confirmatory diagnostic application on Vidas will be the initial focus, bioMerieux is also considering the development of treatment decision and prognostic applications for Anxa 3. The financial details of the deal are not disclosed.
Andre Schrattenholz, chief scientific officer of ProteoSys, said: “It was an obvious choice to partner with bioMerieux because of its strategic focus on oncology, the market leadership of its Vidas platform and its extensive commercial network.”